Primary Myelofibrosis Pipeline Landscape Analysis, 2020 Featuring Novartis, Geron Corporation, NS Pharma, Actuate Therapeutics, Suzhou Zelgen Biopharmaceuticals, CTI BioPharma, Covance, and More - ResearchAndMarkets.com

DUBLIN--()--The "Primary Myelofibrosis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Primary Myelofibrosis Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Primary Myelofibrosis market.

A detailed picture of the Primary Myelofibrosis pipeline landscape is provided, which includes the disease overview and Primary Myelofibrosis treatment guidelines. The assessment part of the report embraces in-depth Primary Myelofibrosis commercial assessment and clinical assessment of the Primary Myelofibrosis pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Myelofibrosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of Primary Myelofibrosis with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Primary Myelofibrosis treatment.
  • Primary Myelofibrosis key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Primary Myelofibrosis market.

Scope of the Report

  • The Primary Myelofibrosis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Primary Myelofibrosis across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Primary Myelofibrosis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
  • Detailed Primary Myelofibrosis research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Primary Myelofibrosis.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Primary Myelofibrosis.
  • In the coming years, the Primary Myelofibrosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Primary Myelofibrosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Primary Myelofibrosis treatment market. Several potential therapies for Primary Myelofibrosis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Primary Myelofibrosis market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Primary Myelofibrosis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions Answered

  • What are the current options for Primary Myelofibrosis treatment?
  • How many companies are developing therapies for the treatment of Primary Myelofibrosis?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Primary Myelofibrosis?
  • How many Primary Myelofibrosis emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Primary Myelofibrosis?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Primary Myelofibrosis market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Primary Myelofibrosis?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Primary Myelofibrosis therapies?
  • What are the clinical studies going on for Primary Myelofibrosis and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Primary Myelofibrosis?
  • How many patents are granted and pending for the emerging therapies for the treatment of Primary Myelofibrosis?

Companies Mentioned

  • Novartis
  • Geron Corporation
  • NS Pharma, Inc.
  • Actuate Therapeutics Inc.
  • Suzhou Zelgen Biopharmaceuticals Co. Ltd.
  • CTI BioPharma
  • Covance

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/x6ksw0

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900